Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

1.

Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.

Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, Stürmer T.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):810-8. doi: 10.1002/pds.3386. Epub 2013 Jan 7.

PMID:
23296544
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer.

Sanoff HK, Carpenter WR, Martin CF, Sargent DJ, Meyerhardt JA, Stürmer T, Fine JP, Weeks J, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Natl Cancer Inst. 2012 Feb 8;104(3):211-27. doi: 10.1093/jnci/djr524. Epub 2012 Jan 20.

PMID:
22266473
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140. Epub 2012 Jun 4.

PMID:
22665536
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.

Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T.

Cancer. 2012 Jun 1;118(11):2925-34. doi: 10.1002/cncr.26622. Epub 2011 Nov 9.

PMID:
22072441
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics.

Dusetzina SB, Mack CD, Stürmer T.

PLoS One. 2013 May 7;8(5):e63973. doi: 10.1371/journal.pone.0063973. Print 2013.

PMID:
23667693
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

PMID:
17049138
[PubMed - indexed for MEDLINE]
Free Article
7.

Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.

Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N.

J Am Geriatr Soc. 2011 Sep;59(9):1717-23. doi: 10.1111/j.1532-5415.2011.03501.x. Epub 2011 Aug 10.

PMID:
21831168
[PubMed - indexed for MEDLINE]
8.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422. Epub 2012 Jan 31.

PMID:
22294436
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007. Epub 2012 Nov 6.

PMID:
23137529
[PubMed - indexed for MEDLINE]
10.
11.

Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.

Zuckerman IH, Rapp T, Onukwugha E, Davidoff A, Choti MA, Gardner J, Seal B, Mullins CD.

J Am Geriatr Soc. 2009 Aug;57(8):1403-10. doi: 10.1111/j.1532-5415.2009.02355.x. Epub 2009 Jun 25.

PMID:
19563521
[PubMed - indexed for MEDLINE]
12.

Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.

Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.

Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

PMID:
23204187
[PubMed - indexed for MEDLINE]
Free Article
13.

Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.

Mullins CD, Hsiao FY, Onukwugha E, Pandya NB, Hanna N.

Cancer. 2012 Jun 15;118(12):3173-81. doi: 10.1002/cncr.26613. Epub 2011 Oct 21.

PMID:
22020739
[PubMed - indexed for MEDLINE]
Free Article
14.

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Yothers G, O'Connell MJ, Lee M, Lopatin M, Clark-Langone KM, Millward C, Paik S, Sharif S, Shak S, Wolmark N.

J Clin Oncol. 2013 Dec 20;31(36):4512-9. doi: 10.1200/JCO.2012.47.3116. Epub 2013 Nov 12. Erratum in: J Clin Oncol. 2014 Mar 10;32(8):866.

PMID:
24220557
[PubMed - indexed for MEDLINE]
15.

Calendar time-specific propensity score analysis for observational data: a case study estimating the effectiveness of inhaled long-acting beta-agonist on asthma exacerbations.

Dilokthornsakul P, Chaiyakunapruk N, Schumock GT, Lee TA.

Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):152-64. doi: 10.1002/pds.3540. Epub 2013 Oct 22.

PMID:
24150874
[PubMed - in process]
16.

Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.

Tournigand C, André T, Bonnetain F, Chibaudel B, Lledo G, Hickish T, Tabernero J, Boni C, Bachet JB, Teixeira L, de Gramont A.

J Clin Oncol. 2012 Sep 20;30(27):3353-60. doi: 10.1200/JCO.2012.42.5645. Epub 2012 Aug 20.

PMID:
22915656
[PubMed - indexed for MEDLINE]
Free Article
17.

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.

Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI.

Ann Intern Med. 2002 Mar 5;136(5):349-57.

PMID:
11874307
[PubMed - indexed for MEDLINE]
18.

Assessing the impact of propensity score estimation and implementation on covariate balance and confounding control within and across important subgroups in comparative effectiveness research.

Girman CJ, Gokhale M, Kou TD, Brodovicz KG, Wyss R, Stürmer T.

Med Care. 2014 Mar;52(3):280-7. doi: 10.1097/MLR.0000000000000064.

PMID:
24374422
[PubMed - indexed for MEDLINE]
19.

Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.

Neugut AI, Matasar M, Wang X, McBride R, Jacobson JS, Tsai WY, Grann VR, Hershman DL.

J Clin Oncol. 2006 May 20;24(15):2368-75. Epub 2006 Apr 17.

PMID:
16618946
[PubMed - indexed for MEDLINE]
Free Article
20.

Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.

Koperna T, Semmler D.

Hepatogastroenterology. 2003 Nov-Dec;50(54):1903-9.

PMID:
14696430
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk